ERYTECH Pharma’s Sickle Cell Treatment Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency June 13, 2012 08:00 AM Eastern Daylight Time LYON, France--( BUSINESS WIRE )-- ERYTECH Pharma, a late stage biopharmaceuticals company focused on orphan oncology and
ERYTECH Pharma Receives € 7 Million from OSEO to Lead the TEDAC Personalized Medicine Project in Cancer Financing of € 6.95 million through grants and redeemable advances from the French public organization OSEO Leader of the collaborative project that aims to create major innovations within a
LYON, France & PHILADELPHIA--( BUSINESS WIRE )-- The first clinical trial using Graspa® on a solid tumor. A good safety profile for Graspa® in last-line therapy patients. A major step forward in its flagship product deployment in solid tumors. ERYTECH Pharma has just completed the enrollment of
Lyon (France) – October 12th, 2010 ERYtech Pharma is pleased to announce it has signed a collaborative research agreement with Genzyme Corporation to explore the feasibility of developing a novel therapeutic enzyme formulation using ERYtech’s proprietary technology.
Lyon (France), Philadelphia (USA), November 24 2009. ERYtech Pharma has been awarded ISO9001:2008 Certification. The International Organization for Standardization is the world’s leading International Standards developer. ISO 9001:2008 specifies the requirements which have been fulfilled by